Key facts
- This page summarizes William L. Macias's Form 4 filing for Immunovant, Inc. (IMVT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Feb 2025, 16:06.
William L. Macias - 19 Feb 2025 Form 4 Insider Report for Immunovant, Inc. (IMVT)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- IMVT
- Reported as of
- 19 Feb 2025
- Net transaction value
- -$42,867
- SEC form
- 4
- Accepted by SEC
- 21 Feb 2025, 16:06:04 UTC
- Prior SEC filing
- 17 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eva Renee Barnett, attorney-in-fact for William L. Macias
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
William L. Macias filed Form 4 for Immunovant, Inc. (IMVT) on 21 Feb 2025.
Change
- Previous filing in this sequence was filed on 17 Jan 2025.
- Current net transaction value: -$42,867.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMVT
transaction
Common Stock
Sale
- Transaction value
- $42,867
- Shares
- -2,055
- Change %
- -0.57%
- Price
- $20.86
- Shares after
- 357,353
- Date
- 19 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Footnote F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.